- Home
- AGIO vs ALIT Comparison
AGIO vs ALIT Comparison
Compare AGIO & ALIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- ALIT
- Stock Information
- Founded
- AGIO 2007
- ALIT 2017
- Country
- AGIO United States
- ALIT United States
- Employees
- AGIO N/A
- ALIT N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- ALIT Business Services
- Sector
- AGIO Health Care
- ALIT Consumer Discretionary
- Exchange
- AGIO Nasdaq
- ALIT Nasdaq
- Market Cap
- AGIO 2.1B
- ALIT 2.0B
- IPO Year
- AGIO 2013
- ALIT N/A
- Fundamental
- Price
- AGIO $36.39
- ALIT $3.60
- Analyst Decision
- AGIO Buy
- ALIT Strong Buy
- Analyst Count
- AGIO 6
- ALIT 6
- Target Price
- AGIO $57.00
- ALIT $8.75
- AVG Volume (30 Days)
- AGIO 771.2K
- ALIT 7.2M
- Earning Date
- AGIO 10-30-2025
- ALIT 11-11-2025
- Dividend Yield
- AGIO N/A
- ALIT 4.46%
- EPS Growth
- AGIO N/A
- ALIT N/A
- EPS
- AGIO 11.13
- ALIT N/A
- Revenue
- AGIO $40,875,000.00
- ALIT $2,311,000,000.00
- Revenue This Year
- AGIO $28.19
- ALIT $0.73
- Revenue Next Year
- AGIO $152.14
- ALIT $3.11
- P/E Ratio
- AGIO $3.27
- ALIT N/A
- Revenue Growth
- AGIO 30.57
- ALIT N/A
- 52 Week Low
- AGIO $23.42
- ALIT $3.55
- 52 Week High
- AGIO $62.58
- ALIT $8.93
- Technical
- Relative Strength Index (RSI)
- AGIO 51.16
- ALIT 33.46
- Support Level
- AGIO N/A
- ALIT $3.57
- Resistance Level
- AGIO $37.18
- ALIT $3.78
- Average True Range (ATR)
- AGIO 1.43
- ALIT 0.15
- MACD
- AGIO -1.50
- ALIT 0.03
- Stochastic Oscillator
- AGIO 88.53
- ALIT 8.40
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About ALIT Alight Inc.
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.